Correction: Targeting the α4–α5 dimerization interface of K-RAS inhibits tumor formation in vivo

Correction to: Oncogene;

https://doi.org/10.1038/s41388-018-0636-y; Published online 20 December 2018

The original version of this article contained errors in the author affiliations which were originally listed as: ²Department of Cell, Jesse Brown VA Medical Center, Chicago, IL, USA. ³Molecular Pharmacology and Experimental Therapeutics, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA. and have now been corrected to: ²Jesse Brown VA Medical Center, Chicago, IL 60612 USA. ³Department of Cell and Molecular Pharmacology and Experimental Therapeutics, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA. This correction has been made in both the PDF and HTML versions of the article.

Additionally, a further error has been corrected on page five in the sentence: Subsequent improvements to the chemistry of these lead compounds have resulted in the most recent interaction, with ARS-1620, which demonstrates selective inhibition of K-RAS(G12C) mutant tumor models in vivo [23]. The word ‘with’ has been removed from this sentence to ensure the correct meaning is communicated, such that the sentence now is: Subsequent improvements to the chemistry of these lead compounds have resulted in the most recent interaction, ARS-1620, which demonstrates selective inhibition of K-RAS(G12C) mutant tumor models in vivo [23].